COPENHAGEN, SEPTEMBER 19, 2016 – A 28-day repeat dosing study in Göttingen minipigs concluded that proprietary formulations of ATx201 are well tolerated and leads to very low systemic exposure. BioAdvice, a leading GLP and GMP contract research organization located in Denmark, conducted the study. The outcome confirms previous studies suggestive of the favorable safety profile of ATx201.
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.
EasyBlog
This is some blog description about this site
AntibioTx Concludes 28-day Repeat Dosing in Göttingen Minipigs with Positive Results
News
09 February 2021
07 January 2021
28 October 2020
21 October 2020
25 August 2020
13 August 2020
22 July 2020
21 July 2020
01 July 2020
01 July 2020
02 April 2020
01 November 2019
01 July 2019
07 February 2019
13 November 2018
29 October 2018
30 July 2018
26 October 2017
24 March 2017
15 March 2017
19 September 2016
06 September 2016
19 August 2016
07 August 2016
07 April 2016
22 March 2016